Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Study on prognostic value of simultaneous [18F]FDG-PET/MRI in refractory myeloma treated w/ anti-BCMA CAR T (ide-cel) finds 3 distinct risk groups, including a very high-risk group defined by both MRI & PET positivity.”
Title: Prognostic value of simultaneous [18F]FDG-PET/MRI in refractory multiple myeloma treated with anti-BCMA CAR T
Authors: Bastien Jamet, Huajun Sun, Chloé François, Hatem Necib, Aurélien Monnet, Éric Frampas, Nicolas Blin, Nicoletta Libera Lilli, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodere, Cyrille Touzeau
You can read the full article on HemaSphere.

You can find other articles featuring Robert Orlowski on OncoDaily.